Jason Zemansky
Stock Analyst at B of A Securities
(3.91)
# 633
Out of 5,090 analysts
48
Total ratings
78.79%
Success rate
50.91%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jason Zemansky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KROS Keros Therapeutics | Maintains: Neutral | $18 → $19 | $21.69 | -12.40% | 3 | Nov 28, 2025 | |
| RCUS Arcus Biosciences | Maintains: Neutral | $17 → $26 | $25.45 | +2.16% | 6 | Nov 28, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $10 → $8 | $3.32 | +140.96% | 3 | Nov 18, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Buy | $8 → $7 | $0.95 | +635.53% | 6 | Nov 18, 2025 | |
| INSM Insmed | Maintains: Buy | $142 → $187 | $204.00 | -8.33% | 11 | Oct 27, 2025 | |
| CYTK Cytokinetics | Maintains: Neutral | $52 → $56 | $65.67 | -14.73% | 5 | Oct 2, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $29 → $31 | $35.00 | -11.43% | 4 | Apr 1, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $36 → $29 | $11.95 | +142.68% | 2 | Nov 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $31 | $20.32 | +52.56% | 3 | Aug 15, 2024 | |
| ESPR Esperion Therapeutics | Downgrades: Underperform | $2.9 → $2.5 | $3.73 | -32.98% | 5 | Jun 20, 2024 |
Keros Therapeutics
Nov 28, 2025
Maintains: Neutral
Price Target: $18 → $19
Current: $21.69
Upside: -12.40%
Arcus Biosciences
Nov 28, 2025
Maintains: Neutral
Price Target: $17 → $26
Current: $25.45
Upside: +2.16%
Rocket Pharmaceuticals
Nov 18, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $3.32
Upside: +140.96%
Werewolf Therapeutics
Nov 18, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $0.95
Upside: +635.53%
Insmed
Oct 27, 2025
Maintains: Buy
Price Target: $142 → $187
Current: $204.00
Upside: -8.33%
Cytokinetics
Oct 2, 2025
Maintains: Neutral
Price Target: $52 → $56
Current: $65.67
Upside: -14.73%
Travere Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $29 → $31
Current: $35.00
Upside: -11.43%
Kura Oncology
Nov 22, 2024
Maintains: Buy
Price Target: $36 → $29
Current: $11.95
Upside: +142.68%
Syndax Pharmaceuticals
Aug 15, 2024
Maintains: Buy
Price Target: $30 → $31
Current: $20.32
Upside: +52.56%
Esperion Therapeutics
Jun 20, 2024
Downgrades: Underperform
Price Target: $2.9 → $2.5
Current: $3.73
Upside: -32.98%